The Impact of COVID-19 on Clinical Trials: Where are We? And Where are We Going?

As the country goes through the phases of reopening, what does that mean for the patient and site experience in clinical trials? PharmaTalkRadio’s Valerie Bowling discusses the future of clinical trials with Dr Ray Dorsey, Matt Kibby and Craig Lipset. Together they address lessons learned from the rapid adoption of technologies to allow for more decentralized trials and their impact on study participation design moving forward, what sponsors can do to set themselves up for success, and the possibility of hybrid trials becoming the new normal for the near future. Guests: Ray Dorsey, MD, is the David M. Levy Professor of Neurology and Director of the Center for Health & Technology at the University of Rochester. Matt Kibby is President, Principal of BBK Worldwide Craig Lipset is the founder of Clinical Innovation Partners and the former Head of Clinical Innovation and Venture Partner at Pfizer You can find all three of our guests speaking at either the upcoming Mobile in Clinical Trials conference or the 10th annual DPHARM conference virtually over September 21st-23rd. For more information about these conferences and other podcasts, visit theconferenceforum.org. For more information about BBK, visit BBKworldwide.com Dr Dorsey's book on Ending Parkinson's Disease can be found on Amazon. You can keep up with Craig Lipset at twitter.com/craiglipset A special thanks to the team at BBK for their support in presenting this podcast.